ATE407697T1 - Erythropoietin immunglobulin fusionsproteine - Google Patents

Erythropoietin immunglobulin fusionsproteine

Info

Publication number
ATE407697T1
ATE407697T1 AT00947408T AT00947408T ATE407697T1 AT E407697 T1 ATE407697 T1 AT E407697T1 AT 00947408 T AT00947408 T AT 00947408T AT 00947408 T AT00947408 T AT 00947408T AT E407697 T1 ATE407697 T1 AT E407697T1
Authority
AT
Austria
Prior art keywords
fusion proteins
cytokine
growth factor
immunolobulin
erythropoietin
Prior art date
Application number
AT00947408T
Other languages
English (en)
Inventor
George Cox
Daniel Doherty
Original Assignee
Bolder Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bolder Biotechnology Inc filed Critical Bolder Biotechnology Inc
Application granted granted Critical
Publication of ATE407697T1 publication Critical patent/ATE407697T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5431—IL-11
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT00947408T 1999-07-13 2000-07-13 Erythropoietin immunglobulin fusionsproteine ATE407697T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14345899P 1999-07-13 1999-07-13

Publications (1)

Publication Number Publication Date
ATE407697T1 true ATE407697T1 (de) 2008-09-15

Family

ID=22504169

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00947408T ATE407697T1 (de) 1999-07-13 2000-07-13 Erythropoietin immunglobulin fusionsproteine

Country Status (10)

Country Link
US (2) US7754855B1 (de)
EP (1) EP1200124B1 (de)
JP (1) JP4944324B2 (de)
AT (1) ATE407697T1 (de)
AU (1) AU782496B2 (de)
CA (1) CA2379388C (de)
DE (1) DE60040225D1 (de)
ES (1) ES2317843T3 (de)
NZ (1) NZ517184A (de)
WO (1) WO2001003737A1 (de)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7304150B1 (en) 1998-10-23 2007-12-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
WO2001081405A2 (en) * 2000-04-21 2001-11-01 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
YU29804A (sh) * 2001-10-11 2006-08-17 Applied Research Systems Ars Holding N.V. Upotreba aktivatora gp-130 u dijabetskoj neuropatiji
KR100467750B1 (ko) * 2001-11-29 2005-01-24 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
KR100467751B1 (ko) * 2001-12-03 2005-01-24 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
ATE459647T1 (de) 2003-04-15 2010-03-15 Glaxosmithkline Llc Humane il-18 substitutionsmutanten und deren konjugate
PT1624891E (pt) 2003-05-06 2010-01-05 Syntonix Pharmaceuticals Inc Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7850970B2 (en) 2003-08-26 2010-12-14 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
ATE555133T1 (de) 2003-11-13 2012-05-15 Hanmi Holdings Co Ltd Igg fc fragment für einen arzneimittelträger und verfahren zu dessen herstellung
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
IL159558A0 (en) * 2003-12-24 2004-06-01 Applied Research Systems Use of il-6 in liver injury
CA2551915C (en) 2003-12-30 2015-06-23 Merck Patent Gesellschaft Mit Beschraenkter Haftung Il-7 fusion proteins
IL161673A0 (en) 2004-04-29 2004-09-27 Applied Research Systems Compositions and methods for therapy of chemotherapy-induced neuropathy
IL161672A0 (en) 2004-04-29 2004-09-27 Yeda Res & Dev Compositions and methods for therapy of chemotherapy-induced neuropathy
JP2007538048A (ja) 2004-05-17 2007-12-27 アレス トレーディング ソシエテ アノニム ヒドロゲル・インターフェロン製剤
UA92146C2 (ru) 2004-06-01 2010-10-11 Эйрэс Трейдинг С.А. Стабилизированная жидкая композиция, которая содержит интерферон
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
MX2007014889A (es) * 2005-05-26 2008-02-19 Schering Corp Fusion de interferon-inmunoglobulina g.
WO2006128176A2 (en) * 2005-05-26 2006-11-30 Nora Llc Composite molecules comprising g-csf function
EP2267024B1 (de) 2005-06-03 2012-05-09 Ares Trading S.A. Herstellung von rekombinantem Il-18 bindendem Protein
PT1891088E (pt) 2005-06-10 2011-12-19 Ares Trading Sa Processo para a purificação da proteína de ligação il-18
WO2006133955A1 (en) 2005-06-17 2006-12-21 Baxter International Inc. Adamts13-comprising compositions having thrombolytic activity
UA97628C2 (ru) 2005-08-16 2012-03-12 Ханми Холдингз Ко., Лтд. Способ получения fc-фрагмента иммуноглобулина, свободного от начального метионинового остатка, в массовом масштабе
JP2009507003A (ja) 2005-09-01 2009-02-19 アレス トレーディング ソシエテ アノニム 視神経炎の治療
EP1790664A1 (de) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoklonale Antikörper gegen Claudin-18 zur Behandlung von Krebs
JP2009524598A (ja) * 2005-12-30 2009-07-02 ファーマエッセンティア コーポレイション 薬剤−高分子結合体
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
AU2007253254B2 (en) 2006-05-24 2013-01-17 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
WO2008101671A2 (en) * 2007-02-19 2008-08-28 Apogenix Gmbh Il-4 fc fusion proteins
WO2009012600A1 (en) 2007-07-26 2009-01-29 Novagen Holding Corporation Fusion proteins
ES2536772T3 (es) * 2007-09-21 2015-05-28 The Regents Of The University Of California El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales
BRPI0821029A2 (pt) 2007-12-20 2015-06-16 Merck Serono Sa Fomulações de peg-interferon-beta
UA101670C2 (ru) 2008-07-23 2013-04-25 Ханми Сайенс Ко., Лтд. Полипептидный комплекс, содержащий непептидильный полимер, который имеет три функциональных конца
EP2421896A1 (de) 2009-04-22 2012-02-29 Merck Patent GmbH Antikörperfusionsproteine mit modifizierten fcrn-bindungsstellen
WO2011020047A1 (en) 2009-08-14 2011-02-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of il-15 to increase thymic output and to treat lymphopenia
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
CN102947341B (zh) * 2010-01-19 2018-07-06 哈佛大学校长及研究员协会 用于病原体检测和治疗的工程化调理素
DE102010010288A1 (de) 2010-03-04 2011-09-08 Wolfgang Poller CCN1 zur Prävention und Therapie von entzündlichen Erkrankungen
WO2011107590A1 (en) 2010-03-04 2011-09-09 Wolfgang Poller Cnn1 (cyr61) for prevention and therapy of inflammatory disease
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
BR112012024565B1 (pt) 2010-03-26 2022-02-08 Trustees Of Dartmouth College Proteína de fusão vista imunossupressora multimérica isolada ou recombinante e composição
AR080993A1 (es) 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
CN102260343A (zh) * 2010-05-25 2011-11-30 健能隆医药技术（上海）有限公司 重组人g-csf二聚体在治疗神经损伤疾病中的用途
KR101337797B1 (ko) * 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
CN102380090A (zh) * 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 G-csf二聚体在治疗嗜中性粒细胞减少症中的应用
US9347951B2 (en) * 2010-10-28 2016-05-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Fusion protein comprising the extracellular domain of a filovirus glycoprotein fused to an immunoglobulin heavy chain constant region
EP2686418A4 (de) 2011-03-17 2015-04-22 Minerva Biotechnologies Corp Verfahren zur herstellung pluripotenter stammzellen
EP2707021B1 (de) * 2011-05-09 2024-02-21 Minerva Biotechnologies Corporation Genetisch manipulierte wachstumsfaktorvarianten
US9320777B2 (en) 2011-05-13 2016-04-26 Bolder Biotechnology, Inc. Methods and use of growth hormone supergene family protein analogs for treatment of radiation exposure
EP3628327A1 (de) 2011-06-24 2020-04-01 The Regents of the University of Colorado, A Body Corporate Zusammensetzungen, verfahren und verwendung für alpha-1-antitrypsin-fusionsmoleküle
WO2013012924A2 (en) 2011-07-18 2013-01-24 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
CN103732240B (zh) * 2011-07-25 2015-12-09 健能隆医药技术（上海）有限公司 G-csf二聚体在制备治疗神经退行性疾病药物中的应用
EP2742064B1 (de) 2011-08-09 2016-07-27 UAB Profarma Derivate aus rekombinanten proteinen, homo-multimere des granulozyten-kolonie-stimulierenden faktors und verfahren zu ihrer herstellung
CN102344938A (zh) * 2011-09-16 2012-02-08 江苏普罗赛生物技术有限公司 哺乳动物细胞大规模生产重组可溶性人干细胞因子与免疫球蛋白Fc片段融合蛋白(sSCF-Fc)的实验技术
KR102323287B1 (ko) 2011-10-05 2021-11-05 원드 매터리얼 인코포레이티드 리튬 이온 배터리용 실리콘 나노구조체 활물질, 및 그에 관련된 공정, 조성물, 구성요소 및 디바이스
US10774132B2 (en) 2012-01-09 2020-09-15 The Scripps Research Instittue Ultralong complementarity determining regions and uses thereof
AU2013202648B2 (en) 2012-01-10 2016-05-19 Konkuk University Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
JP6280031B2 (ja) 2012-03-29 2018-02-14 中外製薬株式会社 抗ｌａｍｐ５抗体およびその利用
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
DK3421486T5 (da) * 2012-06-22 2024-09-16 The Trustees Of Darthmouth College Nye Vista-IG-konstruktioner og anvendelse af Vista-IG til behandling af autoimmune, allergiske og inflammatoriske lidelser
US20150191506A1 (en) * 2012-06-29 2015-07-09 Asahi Kasei Medical Co., Ltd. Adsorbent consisting of carrier which bound with polypeptide comprising b-domain mutant derived from protein a
CN104508132B (zh) 2012-08-02 2017-09-15 弗·哈夫曼-拉罗切有限公司 用于产生作为与惰性免疫球蛋白Fc区Fc融合的可溶FcR的方法及其用途
BR112015002091A2 (pt) 2012-08-02 2017-12-12 Hoffmann La Roche método para a produção de um polipeptídeo, polipeptídeo, uso de um polipeptídeo e composição
JP6368308B2 (ja) 2012-09-07 2018-08-01 トラスティーズ・オブ・ダートマス・カレッジ 癌の診断および治療のためのｖｉｓｔａ調節剤
US9803021B2 (en) 2012-12-07 2017-10-31 The Regents Of The University Of California CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
CN105073781A (zh) 2013-01-11 2015-11-18 加州生物医学研究所 牛融合抗体
KR102073748B1 (ko) 2013-01-31 2020-02-05 한미약품 주식회사 재조합 효모 형질전환체 및 이를 이용하여 면역글로불린 단편을 생산하는 방법
PT2956476T (pt) 2013-02-18 2020-02-21 Vegenics Pty Ltd Moléculas de ligação e usos destas
US20160017017A1 (en) 2013-03-11 2016-01-21 Novo Nordisk Healthcare Ag Growth Hormone Compounds
EP2976642A4 (de) 2013-03-15 2016-09-21 Harvard College Verfahren und zusammensetzungen zur verbesserung der erkennung und/oder aufnahme einer zieleinheit
EP2994758B1 (de) 2013-05-08 2017-12-20 Opthea Limited Biomarker für altersbedingte makuladegeneration (amd)
WO2014190040A1 (en) 2013-05-21 2014-11-27 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
US10093745B2 (en) 2013-05-29 2018-10-09 The Regents Of The University Of California Anti-CSPG4 fusions with interferon for the treatment of malignancy
AR096891A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
JP6463361B2 (ja) 2013-09-08 2019-01-30 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． 第ｖｉｉｉ因子両性イオンポリマーコンジュゲート
LT6161B (lt) * 2013-09-27 2015-06-25 Uab Profarma Granuliocitų kolonijas stimuliuojančio faktoriaus sulieti baltymai su kitais augimo faktoriais, optimaliai su kamieninių ląstelių faktoriumi, ir jų gavimo būdas
EP3083658B1 (de) 2013-12-18 2019-05-08 President and Fellows of Harvard College Detektion gram-positiver bakterien mit crp
RS63295B1 (sr) 2013-12-24 2022-06-30 Janssen Pharmaceutica Nv Anti-vista antitela i fragmenti
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
KR20170010893A (ko) * 2014-06-06 2017-02-01 더 캘리포니아 인스티튜트 포 바이오메디칼 리써치 아미노 말단 면역글로불린 융합 단백질 및 이의 조성물을 구축하는 방법
MX389695B (es) 2014-06-11 2025-03-20 Kathy A Green Uso de agonistas y antagonistas vista para suprimir o aumentar la inmunidad humoral.
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR20210013299A (ko) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
JP2018505911A (ja) 2014-12-05 2018-03-01 イミュネクスト，インコーポレーテッド 推定上のｖｉｓｔａ受容体としてのｖｓｉｇ８の同定と、ｖｉｓｔａ／ｖｓｉｇ８調節剤を産生するためのその使用
AU2015364396B2 (en) * 2014-12-19 2018-08-09 Alkermes, Inc. Single chain Fc fusion proteins
KR101838919B1 (ko) * 2015-03-03 2018-03-15 에이비온 주식회사 인간 인터페론-베타 변이체가 접합된 면역사이토카인 및 이의 제조방법
JP6983075B2 (ja) 2015-06-02 2021-12-17 ノヴォ ノルディスク アー／エス 極性の組換え延長部を有するインスリン
WO2016207717A1 (en) 2015-06-24 2016-12-29 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
US10435457B2 (en) 2015-08-06 2019-10-08 President And Fellows Of Harvard College Microbe-binding molecules and uses thereof
US11229683B2 (en) 2015-09-18 2022-01-25 Bolder Biotechnology, Inc. Hematopoietic growth factor proteins and analogs thereof and angiotensin converting enzyme inhibitors for treatment of radiation exposure
CN108136043B (zh) 2015-10-01 2022-09-06 诺和诺德股份有限公司 蛋白质缀合物
KR102147997B1 (ko) * 2015-10-23 2020-08-25 주식회사 제넥신 피부 주름 개선용 조성물
WO2017100540A2 (en) 2015-12-09 2017-06-15 The California Institute For Biomedical Research Relaxin immunoglobulin fusion proteins and methods of use
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
US10899836B2 (en) 2016-02-12 2021-01-26 Janssen Pharmaceutica Nv Method of identifying anti-VISTA antibodies
CN109789201B (zh) 2016-04-15 2023-06-16 伊穆奈克斯特股份有限公司 抗人vista抗体及其用途
JP7084881B2 (ja) 2016-06-22 2022-06-15 アルカームス インコーポレーテッド Ｉｌ－１０の免疫刺激特性および抗炎症特性を調節するための組成物および方法
CN118307682A (zh) 2016-09-27 2024-07-09 埃皮辛特瑞柯斯公司 免疫调节性融合蛋白
BR122020025384B1 (pt) 2016-12-13 2022-07-12 Delinia, Inc Proteínas de fusão e dimérica, usos das mesmas e composição farmacêutica
CN110505885A (zh) 2017-04-05 2019-11-26 诺和诺德股份有限公司 寡聚体延伸的胰岛素-Fc缀合物
EP3630162A1 (de) * 2017-05-24 2020-04-08 Novartis AG Antikörper-zytokin-gepfropfte proteine und verfahren zur verwendung
JP2020536518A (ja) 2017-09-27 2020-12-17 エピセントアールエックス，インコーポレイテッド 免疫調節融合タンパク質
US20200299349A1 (en) 2017-11-21 2020-09-24 The Board Of Trustees Of The Leland Stanford Junior University Partial agonists of interleukin-2
EP3713582A1 (de) 2017-11-24 2020-09-30 Merck Patent GmbH Cladribin-dosierungsplan zur verwendung bei der behandlung progressiver formen von multipler sklerose
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
CN110396133B (zh) 2018-04-25 2021-07-23 免疫靶向有限公司 一种以白介素12为活性成分的融合蛋白型药物前体
WO2020097946A1 (zh) * 2018-11-18 2020-05-22 杭州博虎生物科技有限公司 一种重组人白细胞介素10融合蛋白及其应用
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
EP4065585B1 (de) 2019-11-25 2025-08-20 Alkermes, Inc. Substituierte makrocyclische verbindungen und zugehörige behandlungsverfahren
EP4090674A4 (de) 2020-01-14 2024-01-24 Synthekine, Inc. Vorgespannte il2-muteins-verfahren und -zusammensetzungen
CA3194812A1 (en) 2020-09-10 2022-03-17 Merck Patent Gmbh Novel treatment regimen for the treatment of autoimmune disorders
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US5023171A (en) * 1989-08-10 1991-06-11 Mayo Foundation For Medical Education And Research Method for gene splicing by overlap extension using the polymerase chain reaction
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US7253264B1 (en) * 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
AU648140B2 (en) * 1991-02-01 1994-04-14 Virtual Drug Development, Inc. Reverse antimicrobial peptides and antimicrobial compositions
US5763584A (en) * 1992-05-18 1998-06-09 Genentech, Inc. Receptor activation with hepatocyte growth factor agonists
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5580853A (en) * 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
US5576191A (en) * 1994-06-17 1996-11-19 Immunex Corporation Cytokine that binds ST2
US6485726B1 (en) * 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6100387A (en) * 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
WO1999002709A1 (en) * 1997-07-10 1999-01-21 Beth Israel Deaconess Medical Center Recombinant erythropoietin / immunoglobulin fusion proteins
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US6242570B1 (en) * 1997-07-10 2001-06-05 Beth Israel Deaconess Medical Center Production and use of recombinant protein multimers with increased biological activity
AU751823B2 (en) 1998-05-14 2002-08-29 Merck Patent Gmbh Fused protein
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents

Also Published As

Publication number Publication date
DE60040225D1 (en) 2008-10-23
AU6102200A (en) 2001-01-30
JP4944324B2 (ja) 2012-05-30
JP2003508023A (ja) 2003-03-04
US7754855B1 (en) 2010-07-13
US20100285014A1 (en) 2010-11-11
EP1200124B1 (de) 2008-09-10
CA2379388C (en) 2012-05-29
AU782496B2 (en) 2005-08-04
CA2379388A1 (en) 2001-01-18
NZ517184A (en) 2004-02-27
ES2317843T3 (es) 2009-05-01
WO2001003737A1 (en) 2001-01-18
EP1200124A4 (de) 2004-09-29
EP1200124A1 (de) 2002-05-02

Similar Documents

Publication Publication Date Title
ATE407697T1 (de) Erythropoietin immunglobulin fusionsproteine
ATE316982T1 (de) Mehrere zytokin-antikörper komplexen
PL336306A1 (en) Proteinous fusions of tgf-beta ii type receptor with a constant immunoglobulin area
LTPA2016028I1 (lt) Imunoglobulino chimeriniai monomero-dimero hibridai
ATE385806T1 (de) Fusionsproteine
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
DK1140173T4 (da) Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf
ATE509032T1 (de) Chimerizierte gm-csf antikörper
BR9704641A (pt) Sistema de expressão de antígenos heterólogos como proteínas de fusão
ATE541935T1 (de) Wachstumshormon fusionprotein
ATE360701T1 (de) Putrescin-n-methyltransferasepromotor
EP0815221A4 (de) Ein neuartiger wachstumfaktor und eine genetische sequenz die für diesen kodiert
FI930626A0 (fi) Proteinstruktur hos vaexttoxingelonin
PT871612E (pt) Isoindolonas fundidas como inibidores de proteina cinase c
WO2002006464A3 (en) Large scale expression and purification of recombinant proteins
DK1208213T3 (da) Fremgangsmåde til fremstilling af proteiner i værtsceller under anvendelse af chaperoniner
AU2013245463B2 (en) Immunoglobulin Chimeric Monomer-Dimer Hybrids
CY1114280T1 (el) Αντισωματα ανταγωνιστων των κυτοκινων θηλαστικων ή οι υποδοχεις τους για την αγωγη της αλλεργιας

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties